Auriga Laboratories, Inc. develops pharmaceutical products based on patented drug delivery technologies in cellular biology, material science, and pharmaceutics. It offers Extendryl, which is used for the treatment of cough and cold medications, and allergy symptoms. The company also offers products for the treatment of gastrointestinal disorders and central nervous system disorders, including pain control. Auriga Laboratories is based in Norcross, Georgia.
Presenting at the upcoming Roth Conference on Feb. 19th
Auriga Labs Reports Preliminary Year-End 2006 Gross Revenues and Provides Forecast for Q1 2007 Monday February 5, 8:45 am ET 2006 Gross Revenues up 96% to $7.4 Million; Forecasts $26 Million in 2007
NORCROSS, Ga.--(BUSINESS WIRE)--Auriga Laboratories, Inc. (OTCBB:ARGA - News), a specialty pharmaceutical company with products for the treatment of acute respiratory diseases, dermatological conditions, and Xerostomia (dry mouth), reported preliminary, unaudited results for year ending December 31, 2006.
For the twelve months ended December 31, 2006, unaudited gross revenues totaled approximately $7.4 million, an increase of 96% from approximately $3.8 million reported for the period April 12, 2005 ("Inception") to December 31, 2005. Unaudited gross profit totaled approximately $4.1 million in 2006, an increase of 105% from $2.0 million reported from Inception to December 31, 2005.
For the first quarter ending March 31, 2007, the company forecasts $6.2 million in gross revenues and expects to be cash flow positive, with gross profit at approximately 60% of revenues. Management maintains its previously issued gross revenue guidance for 2007 at approximately $26 million.
"We have done extraordinarily well in our first full year of operations, as evidenced by strong revenue performance, product line expansion, and development of our sales force," notes Philip S. Pesin, Auriga's CEO. "We remain confident that we'll reach or exceed our goals for 2007, especially as we gear up to launch at least four new and/or reformulated products this quarter while our sales force continues to grow exponentially."
Auriga recently reported that independent monthly IMS data shows Auriga's total dispensed prescriptions for its Extendryl family of products increased 146% in December 2006, as compared to December 2005, and that its sales force had expanded to 100 sales associates from nine in less than seven months. The company is now targeting 175 associates by the end of the first quarter 2007.
Also during the first quarter 2007, Auriga plans to launch Aquoral(TM), a prescription-only product designed to treat the widespread condition of Xerostomia (dry mouth) and its Zinx(TM) family of respiratory prescription and over-the-counter products.
About Auriga Laboratories(TM)
Auriga Laboratories is a specialty pharmaceutical company capitalizing on high-revenue markets and opportunities in the pharmaceutical industry through proactive sales, integrated marketing, and advanced in-house drug development capabilities. The company's high-growth business model combines acquisition of proven brand names, powerful product development strategies and rapidly-growing national sales teams and marketing operations. Auriga acquires valuable brand portfolios that are no longer a strategic focus for large pharmaceutical companies, then capitalizes on untapped marketplace opportunities through brand extension and directed sales/marketing programs. The company's drug-development pipeline leverages novel material science and advanced drug delivery technologies to produce improved formulations of successful brands to further expand markets, sales and clinical indications for proven, successful products. Auriga's exclusive prescription product portfolio currently includes Aquoral(TM) for the treatment of Xerostomia, Akurza(TM) and Xyralid(TM) dermatology products, and the Zinx(TM), Extendryl®, and Levall® families of products for relief of symptoms associated with a range of acute respiratory diseases. For more information, visit: www.aurigalabs.com.
Up 25% today.
Radaring.
-------------------- Stick with Repo's plan in '07 - FRPT/DKAM!
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
